Gentronix, an Alderley Park, Alderley Edge, UK-based contract research organisation (CRO) which is a leader in the field of genetic toxicology, raised £700k in funding.
The round was led by existing investor Mercia.
The latest round, which includes a number of private investors, follows Gentronix’s recent acquisition of the Big Blue® transgenic mutation assay from Merck KGaA. It will be used to fund the onboarding and delivery of the new service and expand its genetic, skin and ocular toxicology services.
Led by Matt Tate, Managing Director, Gentronix provides companies developing new chemical or pharmaceutical products with toxicology tests required by regulators to show that they are safe to use. Based at Alderley Park in Cheshire, it currently employs over 40 staff including a team of expert toxicologists and serves clients including top five pharmaceutical, chemical and agrochemical organisations.
The Big Blue® assay is one of only three tests in the world used for the final assessment of potential mutagenicity – the risk that a substance could cause genetic mutations that could be damaging to human health and the environment.